Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...iagnosis
Recommendation 1.1The diagnosis of...
...dation 1.2Radiographic diagnosis of metastatic...
Treatment
Treatmen...
...ation 2.1Select patients (see Practical Info...
...ndation 3.1Select patients with meta...
...1. First-Line Treatmenta Select cases...
...tion 3.2All patients with metastatic cle...
...ation 3.3Patients with favorable risk disease...
....4Select patients with metastatic cl...
...tion 3.5The use of high dose interleu...
...ation from 2023 Rapid Recommendation U...
...on 3.6Treatment with IpiNivoCabo is not recom...
...tion 4.1Nivolumab or cabozantinib should...
...endation 4.2Patients progressing on co...
...n 4.3Patients who progress after initial therapy...
...endation 4.4For patients on immunothera...
...ecommendation 5.1For patients with...
...n 5.2For patients undergoing complete m...
...ation 6.1.1Patients with symptomatic bone met...
...ndation 6.1.2Patients with bone me...
...econd-Line or Greater Treatment...
...e 3. Metastases-Directed Tr...
...6.1.3No recommendation regarding optimal systemic...
Recommendation 6.2.1Patients with brain metas...
...commendation 6.2.2No recommendation regard...
...6.3Patients with metastatic clear cell...
...re 4. Special Patient Subtyp...
...believes that cancer clinical trials are vi...